<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054496</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270723</org_study_id>
    <secondary_id>CCF-IRB-5478</secondary_id>
    <nct_id>NCT00054496</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme</brief_title>
  <official_title>Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary&#xD;
      for cancer cell growth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have&#xD;
      recurrent or progressive glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with recurrent or progressive glioblastoma&#xD;
           multiforme treated with erlotinib.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of tumor EGFR amplification in predicting response to treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme&#xD;
&#xD;
               -  Radiographic evidence of recurrence or progression&#xD;
&#xD;
                    -  Biopsies to confirm tumor recurrence allowed if a sufficent percentage of&#xD;
                       cases are confirmed to be recurrent tumor&#xD;
&#xD;
          -  Previously treated with optimal radiotherapy and at least 1 cytotoxic chemotherapy&#xD;
             regimen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times normal&#xD;
&#xD;
          -  ALT no greater than 3 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  BUN no greater than 1.5 times normal OR&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No medical condition that would interfere with oral administration of erlotinib&#xD;
&#xD;
          -  No other medical or psychiatric illness that would preclude study therapy&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 3 years except surgically cured carcinoma in situ&#xD;
             of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy for brain cancer&#xD;
&#xD;
          -  No concurrent biologic therapy for brain cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy for brain cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent glucocorticosteroids allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy for brain cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior epidermal growth factor receptor (EGFR) inhibitor&#xD;
&#xD;
          -  No concurrent EGFR inhibitor&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No concurrent anti-epileptic agents other than modest- or non-enzyme-inducing drugs&#xD;
             such as the following:&#xD;
&#xD;
               -  Gabapentin&#xD;
&#xD;
               -  Lamotrigine&#xD;
&#xD;
               -  Divalproex&#xD;
&#xD;
               -  Felbamate&#xD;
&#xD;
               -  Levetiracetam&#xD;
&#xD;
               -  Tiagabine&#xD;
&#xD;
               -  Topiramate&#xD;
&#xD;
               -  Zonisamide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Vogelbaum, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente</last_name>
      <phone>866-223-8100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

